Study details
Enrolling now
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Divaya Bhutani
NCT IDNCT05346809ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
39
Study length
about 3.5 years
Ages
18+
Locations
2 sites in MI, NY
About this study
This trial is testing if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma after stem cell transplant. Participants will receive either standard procedures or Isatuximab along with those procedures, randomly assigned by a computer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Standard Procedures
- 2.Take Isatuximab
PhasePhase 2
DrugIsatuximab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
isatuximab
Endpoints
Secondary: Number of Adverse Events
Body systems
Oncology